Dr. Lancet on CPX-351 Compared to Chemotherapy for Older Adults with AML
Dr. Lancet explains CPX-351 treatment, compared to induction therapy, for older adult patients with acute myeloid leukemia.
ALLRecovery – Part 3: Chemotherapy for Acute Lymphoblastic Leukemia
Created by YJZhang Biomedical Visuals Voiced by Jessica Zhang https://yjzvisuals.com
Can 7+3 as induction therapy for acute myeloid leukemia (AML) be optimized?
Utz Krug, MD, from the Leverkusen Clinic, Leverkusen, Germany, discusses whether 7+3 as induction therapy for acute myeloid leukemia (AML) can be optimized at the International Symposium on Acute Leukemias (ISAL) 2017 in Munich, Germany. [More]
Understanding your treatment: Taxol/Erbitux chemotherapy
This video describes the schedule and treatment with Taxol/Erbitux chemotherapy for head and neck cancer. You should first watch the general information chemotherapy video on the charlottecancer channel before viewing this.
Acute Myeloid Leukemia: An Overview and Updates
This presentation provides information to assist clinicians in identifying patients with Acute Myeloid Leukemia and selecting appropriate treatment options based on clinical and genetic variables. The presentation also reviews appropriate criteria for investigational/novel therapies and [More]
Day 1 Acute myeloid leukemia AML CHEMO treatments start
We were doing unboxings but we decided to document this fight, this war, battle by battle, from her point of view, our point of view. My wife was diagnosed with leukemia on a Friday and [More]
Debates Surrounding Induction Chemotherapy in HNSCC
Panelists Ezra Cohen, MD; Tanguy Y. Seiwert, MD; and Viktor Grünwald, MD, provide insight on the debate surrounding induction chemotherapy in patients with head and neck cancer.